Astellas Pharma, Inc./ US04623U1025 /
| 2024-05-10 9:59:59 PM | Chg. -0.1800 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 9.7200USD | -1.82% | 145,881 Turnover: 822,120.3382 |
-Bid Size: - | -Ask Size: - | 25.77 bill.USD | - | - |
Assets
|
2021 IFRS in mill. JPY |
||
|---|---|---|---|
| Property and Equipment | 269,044 | ||
| Intangible Assets | 623,431 | ||
| Long-Term Investments | - | ||
| Fixed Assets | 1.41 mill. | ||
| Inventories | 153,072 | ||
| Accounts Receivable | 412,258 | ||
| Cash and Cash Equivalents | 315,986 | ||
| Current Assets | 923,354 | ||
| Total Assets | 2.33 mill. | ||
Liabilities
|
2021 IFRS in mill. JPY |
||
|---|---|---|---|
| Accounts Payable | 131,415 | ||
| Long-term debt | - | ||
| Liabilities to Banks | - | ||
| Provisions | 28,224 | ||
| Liabilities | 872,087 | ||
| Share Capital | - | ||
| Total Equity | 1.46 mill. | ||
| Minority Interests | - | ||
| Total liabilities equity | 2.33 mill. | ||
Income Statement
|
2021 IFRS in mill. JPY |
||
|---|---|---|---|
| Revenues | 1.3 mill. | ||
| Depreciation (total) | 28,283 | ||
| Operating Result | 155,686 | ||
| Interest Income | 1,200 | ||
| Income Before Taxes | - | ||
| Income Taxes | 32,800 | ||
| Minority Interests Profit | - | ||
| Net Income | 124,086 | ||
Per Share
Cash Flow
|
2021 IFRS in mill. JPY |
||
|---|---|---|---|
| Cash Flow from Operating Activities | 257,444 | ||
| Cash Flow from Investing Activities | -62,413 | ||
| Cash Flow from Financing | -216,298 | ||
| Decrease / Increase in Cash | - | ||
| Employees | 14,520 | ||
